title: The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy.
abstract: Research with high throughput technologies has propitiated the segmentation of different types of tumors into very small subgroups characterized by the presence of very rare molecular alterations. The identification of these subgroups and the apparition of new agents targeting these infrequent alterations are already affecting the way in which clinical trials are being conducted with an increased need to identify those patients harboring specific molecular alterations. In this review we describe some of the currently ongoing and future studies at the Institut Gustave Roussy that aim for the identification of potential therapeutic targets for cancer patients with the incorporation of high throughput technologies into daily practice including aCGH, next generation sequencing and the creation of a software that allows for target identification specific for each tumor. The initial intention is to enrich clinical trials with cancer patients carrying certain molecular alterations in order to increase the possibility of demonstrating benefit from a targeted agent. Mid and long term aims are to facilitate and speed up the process of drug development as well as to implement the concept of personalized medicine.
authors.affiliation: Department of Medical Oncology, Institut de Cancerologie Gustave Roussy, 94805 Villejuif, France.
authors.forename: Monica
authors.initials: M
authors.lastname: Arnedos
authors.forename: Fabrice
authors.initials: F
authors.lastname: André
authors.forename: Françoise
authors.initials: F
authors.lastname: Farace
authors.forename: Ludovic
authors.initials: L
authors.lastname: Lacroix
authors.forename: Benjamin
authors.initials: B
authors.lastname: Besse
authors.forename: Caroline
authors.initials: C
authors.lastname: Robert
authors.forename: Jean Charles
authors.initials: JC
authors.lastname: Soria
authors.forename: Alexander M M
authors.initials: AM
authors.lastname: Eggermont
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis / Q000628:therapy*; D009360:Neoplastic Cells, Circulating; D057285:Precision Medicine